Pharmaceutical Executive

Pharmaceutical Executive: April 2026
Volume: 46
Issue: 3

Pharmaceutical Executive: March 2026
Volume: 46
Issue: 2

Pharmaceutical Executive: February 2026
Volume: 46
Issue: 1

Pharmaceutical Executive: December 2025
Volume: 45
Issue: 9

Pharmaceutical Executive: October 2025
Volume: 45
Issue: 8

Pharmaceutical Executive: September 2025
Volume: 45
Issue: 7

Pharmaceutical Executive: August 2025
Volume: 45
Issue: 6

Pharmaceutical Executive: June 2025
Volume: 45
Issue: 5

Pharmaceutical Executive: May 2025
Volume: 45
Issue: 4

Pharmaceutical Executive: April 2025
Volume: 45
Issue: 3

Pharmaceutical Executive: March 2025
Volume: 45
Issue: 2

Pharmaceutical Executive: February 2025
Volume: 45
Issue: 1

Pharmaceutical Executive: December 2024
Volume: 44
Issue: 12

Pharmaceutical Executive: November 2024
Volume: 44
Issue: 11

Pharmaceutical Executive: October 2024
Volume: 44
Issue: 10

Pharmaceutical Executive: September 2024
Volume: 44
Issue: 9

Pharmaceutical Executive: July/August 2024
Volume: 44
Issue: 7/8

Pharmaceutical Executive: June 2024
Volume: 44
Issue: 6

Pharmaceutical Executive: May 2024
Volume: 44
Issue: 5

Pharmaceutical Executive: April 2024
Volume: 44
Issue: 4

Pharmaceutical Executive: March 2024
Volume: 44
Issue: 3

Pharmaceutical Executive: February 2024
Volume: 44
Issue: 1

Pharmaceutical Executive: December 2023
Volume: 43
Issue: 12

Pharmaceutical Executive: November 2023
Volume: 43
Issue: 11

Pharmaceutical Executive: October 2023
Volume: 43
Issue: 10

Pharmaceutical Executive: September 2023
Volume: 43
Issue: 9

Pharmaceutical Executive: August 2023
Volume: 43
Issue: 8

Pharmaceutical Executive: July 2023
Volume: 43
Issue: 7

Pharmaceutical Executive: June 2023
Volume: 43
Issue: 6

Pharmaceutical Executive: May 2023
Volume: 43
Issue: 5
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly’s Oral Weight Loss Pill Prescribed Over 1,000 Times in First Days on Market
2
The Turning Point for Oral Biologics: Q&A With Morten Graugaard
3
Inside Pharma's Revenue Engine: The Gross-to-Net Reckoning
4
Positioning A New Standard of Care in Relapsed Multiple Myeloma: Q&A with Imran Khan, MD, PhD
5
